Utility of the novel bladder preservation therapy, BOAI-CDDP-radiation (OMC-regimen), for elderly patients with invasive bladder cancer

International Journal of Oncology

Volumn 38, Issue 1, 2011, Pages 13-24

  Azuma, Haruhito ^a   Inamoto, Teruo ^a   Ibuki, Naokazu ^a   Ubai, Takanobu ^a   Kotake, Yatsugu ^a   Takahara, Kiyoshi ^a   Kiyama, Satoshi ^a   Nomi, Hayahito ^a   Uehara, Hiroshi ^a   Komura, Kazumasa ^a   Yamamoto, Kazuhiro ^a   Narumi, Yoshihumi ^a   Katsuoka, Yoji ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Balloon occluded arterial infusion; Elderly patient; Hemodialysis; Invasive bladder cancer

Indexed keywords

CISPLATIN; GEMCITABINE;

AGED; ARTICLE; BALLOON OCCLUSION; BLADDER BIOPSY; BLADDER CANCER; CANCER INVASION; CANCER RADIOTHERAPY; CYSTECTOMY; CYSTITIS; DRUG MEGADOSE; FEMALE; GERIATRIC CARE; GROUPS BY AGE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BALLOON DILATION; CISPLATIN; COMBINED MODALITY THERAPY; CYSTECTOMY; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFUSIONS, INTRA-ARTERIAL; MALE; NEOPLASM STAGING; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 78650836301     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000819     Document Type: Article

References (23)

1. Tran E, Souhami L, Tanguay S and Rajan R: Bladder conservation treatment in the elderly population: results and prognostic factors of muscle-invasive bladder cancer. Am J Clin Oncol 32: 333-337, 2009.
2. Weizer AZ, Joshi D, Daignault S, et al: Performance status is a predictor of overall survival of elderly patients with muscle invasive bladder cancer. J Urol 177: 1287-1293, 2007.
3. Hoshi S, Shintaku I, Suzuki K, et al: Bladder preservation by internal iliac arterial infusion chemotherapy and irradiation in T3 bladder carcinoma patients over the age of 70 years. Tohoku J Exp Med 192: 249-258, 2000.
4. Kaufman DS, Winter KA, Shipley WU, et al: The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent CDDP and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 5: 471-476, 2000.
5. Rodel C, Grabenbauer GG, Kuhn R, et al: Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 20: 3061-3071, 2002.
6. Nielsen ME, Shariat SF, Karakiewicz PI, et al: Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol 51: 698-706, 2007.
7. Shipley WU, Winter KA, Kaufman DS, et al: Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 16: 3576-3583, 1998.
8. Tester W, Caplan R, Heaney J, et al: Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 14: 119-126, 1996.
9. Shipley WU, Prout GRJ, Einstein AB, et al: Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA 258: 931-935, 1987.
10. Hagan MP, Winter KA, Kaufman DS, et al: RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 57: 665-672, 2003.
11. Greene FL, Page DL and Fleming ID: AJCC cancer staging manual. 6th edition. Springer Verlag, New York, 2002.
12. Ficcara V, Dalpiaz O, Alrabi N, Novara G, Galfano A and Artibani W: Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma. BJU Int 95: 786-790, 2005. (Pubitemid 40547207)
13. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
14. Johansson SL and Cohen SM: Epidemiology and etiology of bladder cancer. Semin Surg Oncol 13: 291-298, 1997.
15. Collins JM: Pharmacokinetic rationale for intraarterial therapy. In: Cancer Chemotherapy, Challenges for the Future. Kimura K (ed). Vol. 4. Excepta Medica, Amsterdam, 1989.
16. Mitsuzane K, Kawabata M, Terada M, Nomura S, Sato M and Yamada R: Balloon-occluded arterial infusion as chemotherapy in bladder cancer - long-term results. Gan To Kagaku Ryoho 17: 1701-1704, 1990.
17. Cvitkovic E, Spaulding J, Bethune V, Martin J and Whitmore WF: Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer 39: 1357-1361, 1977. (Pubitemid 8108285)
18. Douple EB and Richmond RC: A review of platinum complex biochemistry suggests a rationale for combined platinum-radiotherapy. Int J Radiat Oncol Biol Phys 8: 1335-1339, 1979.
19. Abbott DW, Freeman ML and Holt JT: Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst 90: 978-985, 1998.
20. Brown JM and Wouters BG: Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 59: 1391-1399, 1999.
21. Chadwick KH, Leenhouts HP, Szumiel I and Nias AH: An analysis of the interaction of a platinum complex and radiation with CHO cells using the molecular theory of cell survival. Int J Radiat Biol Relat Stud Phys Chem Med 6: 511-524, 1976.
22. Belt RJ, Himmelstein KJ, Patton TF, Bannister SJ, Sternson LA and Repta AJ: Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammine-platinum (II). Cancer Treat Rep 63: 1515-1521, 1979.
23. Himmelstein KJ, Patton TF, Belt RJ, Taylor S, Repta AJ and Sternson LA: Clinical kinetics on intact cisplatin and some related species. Clin Pharmacol Ther 29: 658-664, 1981.